Brief report: Combination of Osimertinib and Dacomitinib to mitigate primary and acquired resistance in EGFR-mutant lung adenocarcinomas.
Arielle ElkriefAlex MakhninKhadeja A MosesLinda S AhnIsabel R PreeshagulAfsheen N IqbalSara A HayesAndrew J PlodkowskiPaul K PaikMarc LadanyiMark G KrisGregory J RielyFranziska MichorHelena Alexandra YuPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
We observed no acquired secondary EGFR alterations with dual inhibition of EGFR as upfront treatment, but this regimen was associated with greater toxicity. The combination was not effective in reversing acquired resistance after development of a second-site acquired EGFR alteration. Our study highlights the need to develop better strategies to address on-target resistance in patients with EGFR-mutant lung cancers.